No description
-
2015 (v1)PublicationUploaded on: April 14, 2023
-
2024 (v1)Publication
Background: There is little information on the trajectory and developmental fate of Lin(-)CD34(+)DNAM-1(bright) CXCR4(+) progenitors exiting bone marrow during systemic inflammation. Objective: To study Lin(-)CD34(+)DNAM-1(bright) CXCR4(+) cell circulation in cancer patients, to characterize their entry into involved lung tissue and to...
Uploaded on: July 3, 2024 -
2015 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Background: The demonstration of EGFR T790M gene mutation in plasma is crucial to assess the eligibility of Non Small Cell Lung Cancer (NSCLC) patients, who have acquired resistance to first or second generation Tyrosine Kinase Inhibitors (TKIs), to receive a subsequent treatment with osimertinib. Since circulating tumor DNA (ctDNA) is present...
Uploaded on: April 14, 2023 -
2020 (v1)Publication
Due to their peculiar mechanism of action, the evaluation of radiological response to immune checkpoint inhibitors (ICI) presents many challenges in solid tumors. We aimed to compare the evaluation of first response to Nivolumab by means of CT-based criteria with respect to fluorodeoxyglucose positron emission tomography (FDG-PET) response...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
Background: Rare cases of severe myocarditis are reported during treatment with nivolumab. Troponin, a biomarker of cardiac damage, is a key component of the diagnostic workup of many cardiac disorders, including myocarditis. This study investigates the role of troponin to assess cardiac involvement during nivolumab therapy for non-small cell...
Uploaded on: April 14, 2023 -
2019 (v1)PublicationCorrelation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
Reliable predictors of benefit from immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are still limited. We aimed to evaluate the association between the expression of selected molecules involved in immune response and clinical outcomes in NSCLC patients receiving nivolumab. In our study, the outcomes of 46 NSCLC patients...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Monoclonal antibodies targeting PD-1 are used for treating NSCLC. To date, proprotein convertase subtilisin/kexin type 9 (PCSK9) has been poorly investigated in the oncologic field. Here, we aimed at evaluating whether serum PCSK9 might represent a predictive factor for OS in older patients with advanced NSCLC under nivolumab treatment. Among...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Treatment with nivolumab improves survival and response rate in non-small cell lung cancer (NSCLC). Nevertheless, due to its high financial cost, identifying predictors of response to treatment has become an urgent need. Here, we focused on serum osteopontin (OPN), a pleiotropic protein overexpressed in lung cancer and involved in the immune...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
We aimed to evaluate the relationships between circulating tumor cells (CTCs) or plasma cell–free DNA (cfDNA) on one side and a comprehensive range of18F-FDG PET/CT–derived parameters on the other side in chemotherapy-naive patients with advanced non–small cell lung cancer (NSCLC). Methods: From a group of 79 patients included in a trial...
Uploaded on: April 14, 2023 -
2020 (v1)Publication
Radiomics is defined as the use of automated or semi-automated post-processing and analysis of multiple features derived from imaging exams. Extracted features might generate models able to predict the molecular profile of solid tumors. The aim of this study was to develop a predictive algorithm to define the mutational status of epidermal...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
Women treated for breast cancer (BC) are at risk of developing secondary tumors, such as lung cancer (LC). Since rare germline variants have been linked to multiple cancer development, we hypothesized that BC survivors might be prone to develop LC as a result of harboring rare variants. Sixty patients with LC with previous BC (the study...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Simple Summary To date, the five-year survival rate of early stages of non-small cell lung cancer (NSCLC) is still disappointing and reliable prognostic factors are mandatory. Here, we performed in-depth high-throughput analyses of plasma circulating markers, including exosomal microRNAs and peptidome to identify a prognostic score. The miRnome...
Uploaded on: February 22, 2023 -
2023 (v1)Publication
The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy remains limited to a subgroup of patients. Circulating immune checkpoints in soluble (s) form and associated with extracellular vesicles (EVs) represent promising...
Uploaded on: February 14, 2024